156 related articles for article (PubMed ID: 34349654)
21. Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries.
Gozzo L; Romano GL; Brancati S; Cicciù M; Fiorillo L; Longo L; Vitale DC; Drago F
Front Pharmacol; 2021; 12():823199. PubMed ID: 35185551
[TBL] [Abstract][Full Text] [Related]
22. Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network.
Heard JM; Vrinten C; Schlander M; Bellettato CM; van Lingen C; Scarpa M;
Orphanet J Rare Dis; 2020 Jan; 15(1):3. PubMed ID: 31907071
[TBL] [Abstract][Full Text] [Related]
23. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
24. European Medicines Agency support mechanisms fostering orphan drug development.
Butlen-Ducuing F; Rivière F; Aarum S; Llinares-Garcia J
Drug News Perspect; 2010; 23(1):71-81. PubMed ID: 20155221
[TBL] [Abstract][Full Text] [Related]
25. Bulgarian rheumatology: science and practice in a cost-constrained environment.
Georgiev T; Stoilov R
Rheumatol Int; 2019 Mar; 39(3):417-429. PubMed ID: 30413925
[TBL] [Abstract][Full Text] [Related]
26. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of the evolution in the access to orphan medicines in Spain].
Mestre-Ferrándiz J; Iniesta M; Trapero-Bertran M; Espín J; Brosa M
Gac Sanit; 2020; 34(2):141-149. PubMed ID: 31014554
[TBL] [Abstract][Full Text] [Related]
28. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
29. Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
Leyens L; Brand A
Public Health Genomics; 2016; 19(3):187-91. PubMed ID: 27238553
[TBL] [Abstract][Full Text] [Related]
30. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
Winstone J; Chadda S; Ralston S; Sajosi P
Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
[TBL] [Abstract][Full Text] [Related]
31. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
32. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI.
Schlander M; Beck M
Curr Med Res Opin; 2009 May; 25(5):1285-93. PubMed ID: 19366306
[TBL] [Abstract][Full Text] [Related]
33. An Overview of the Orphan Medicines Market in Turkey.
Koçkaya G; Wertheimer AI; Kilic P; Tanyeri P; Mert Vural I; Akbulat A; Artiran G; Kerman S
Value Health Reg Issues; 2014 Sep; 4():47-52. PubMed ID: 29702806
[TBL] [Abstract][Full Text] [Related]
34. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
35. [Orphan diseases and orphan medicines: a Belgian and European study].
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
[TBL] [Abstract][Full Text] [Related]
36. National Health Insurance Fund's relationship to retail drug outlets: a Tanzania case study.
Embrey M; Mbwasi R; Shekalaghe E; Liana J; Kimatta S; Ignace G; Dillip A; Hafner T
J Pharm Policy Pract; 2021 Feb; 14(1):21. PubMed ID: 33593420
[TBL] [Abstract][Full Text] [Related]
37. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
[No Abstract] [Full Text] [Related]
38. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
Enzmann H; Broich K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
[TBL] [Abstract][Full Text] [Related]
39. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
Ferrario A
Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
[TBL] [Abstract][Full Text] [Related]
40. Pharmacy Practice and Education in Bulgaria.
Petkova V; Atkinson J
Pharmacy (Basel); 2017 Jun; 5(3):. PubMed ID: 28970446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
